Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.201
Sell
RSI(14)
36.370
Neutral
STOCH(KDJ)(9,3,3)
23.971
Neutral
ATR(14)
0.381
High Vlolatility
CCI(14)
-79.023
Neutral
Williams %R
79.948
Sell
TRIX(12,20)
-0.595
Sell
StochRSI(14)
75.757
Buy
Search
Clene Inc.
CLNNAdd to Watchlist
5.015USD
-0.025-0.50%
Close 07-31 16:00（ET）Quotes delayed by 15 min
59.07MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey ChartIntraday
1m
30m
1h
D
W
M
D
Today
-0.50%
5 Days
-6.96%
1 Month
-18.52%
6 Months
+22.62%
Year to Date
-14.57%
1 Year
+41.67%
Key Figures
5.040Open
5.427High
33.75KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
0.29%Turnover Ratio
5.040Prev. Close
4.940Low
135.12KTurnover
LossP/E Static
-3.14P/B
0.00%Div Yield TTM
-142.67%ROA
13.50052wk High
0.51Volume Ratio
-39.40MNet Profit
11.78MShares
-3.2645EPS TTM
0.92Beta
-1738.36%ROE
2.60052wk Low
9.67%Amplitude
100.00%Gross Margin
59.07MMarket Cap
-2.40Reward/Risk
6.74%Risk Rate
TradingKey Stock Score of Clene Inc.
Currency: USD Updated: 2026-07-31Key Insights
Clene Inc.'s fundamentals are relatively stable, and its growth potential is high.Its valuation is considered fairly valued, ranking 157 out of 385 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 32.20.In the medium term, the stock price is expected to trend down.Despite a very weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Clene Inc.'s Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Clene Inc. Highlights
StrengthsRisks
Clene Inc. is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson's disease, and multiple sclerosis. It specializes in the discovery, development, and commercialization of clean-surfaced nanotechnology (CSN) therapeutics. CNM-Au8, the lead asset, is a concentrated aqueous suspension of catalytically active, clean-surfaced, faceted gold nanocrystals. CNM-Au8’s mechanism of action targets mitochondrial dysfunction by catalyzing the production of nicotinamide adenine dinucleotide. Its CNM-ZnAg is a broad-spectrum antiviral, antibacterial agent comprised of zinc (Zn2+) and silver (Ag+) ions under development to treat infectious disease and to provide immune support for symptom resolution. Its CNM-AgZn17 is a gel polymer suspension of Zn2+ and Ag+ under development for the treatment of infectious diseases and to support wound healing.
Growing
The company is in a growing phase, with the latest annual income totaling USD 200.00K.
Fairly Valued
The company’s latest PE is -1.54, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 2.19M shares, decreasing 1.60% quarter-over-quarter.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.77.
Analyst Rating
Based on
5
analysts
Buy
Current Rating
32.200
Target Price
+582.20%
Upside Space
Clene Inc. News
More news coming soon, stay tuned...
Earnings Forecast
Analyst Rating
Based on
5
analysts
Buy
Current Rating
32.200
Target Price
+582.20%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
496
Total
6
Median
7
Average
Company name
Ratings
Analysts
Clene Inc.
CLNN
5
Beigene Ltd
ONC
28
argenx SE
ARGX
26
Ionis Pharmaceuticals Inc
IONS
26
IQVIA Holdings Inc
IQV
25
Insmed Inc
INSM
23
1
2
3
...
99
Indicators
Moving Average
Indicators
Value
Direction
MA5
5.045
Sell
MA10
5.349
Sell
MA20
5.722
Sell
MA50
5.913
Sell
MA100
6.024
Sell
MA200
6.382
Sell
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Clene Inc. Info
Clene Inc. is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson's disease, and multiple sclerosis. It specializes in the discovery, development, and commercialization of clean-surfaced nanotechnology (CSN) therapeutics. CNM-Au8, the lead asset, is a concentrated aqueous suspension of catalytically active, clean-surfaced, faceted gold nanocrystals. CNM-Au8’s mechanism of action targets mitochondrial dysfunction by catalyzing the production of nicotinamide adenine dinucleotide. Its CNM-ZnAg is a broad-spectrum antiviral, antibacterial agent comprised of zinc (Zn2+) and silver (Ag+) ions under development to treat infectious disease and to provide immune support for symptom resolution. Its CNM-AgZn17 is a gel polymer suspension of Zn2+ and Ag+ under development for the treatment of infectious diseases and to support wound healing.
Ticker SymbolCLNN
CompanyClene Inc.
CEOEtherington (Robert)
Websitehttps://clene.com/
Shareholders
Related Instruments
-0.53%
+0.27%
-0.92%
-2.51%
+0.32%
-1.45%
-0.64%
-0.82%
-8.79%
+0.52%
+0.68%
-0.95%
-0.71%
+0.44%
-1.08%
+3.29%
0.00%
+1.30%
-0.90%
-2.15%Popular Instruments
52378.000
+109.000 (+0.21%)
28160.900
-37.600 (-0.13%)
7475.100
+30.800 (+0.41%)
14749.000
-90.000 (-0.61%)
62852.000
-742.000 (-1.17%)
6365.400
-1.000 (-0.02%)
85.934
+2.764 (+3.32%)
308.910
-24.520 (-7.35%)
200.750
+5.710 (+2.93%)
4041.430
-61.400 (-1.50%)
FAQs
What is the current price of Clene Inc. (CLNN)?
The current price of Clene Inc. (CLNN) is 5.04.
What is the symbol of Clene Inc.?
The ticker symbol of Clene Inc. is CLNN.
What is the 52-week high of Clene Inc.?
The 52-week high of Clene Inc. is 13.50.
What is the 52-week low of Clene Inc.?
The 52-week low of Clene Inc. is 2.60.
What is the market capitalization of Clene Inc.?
The market capitalization of Clene Inc. is 51.51M.
Is Clene Inc. (CLNN) currently rated as Buy, Hold, or Sell?
According to analysts, Clene Inc. (CLNN) has an overall rating of Buy, with a price target of 32.20.
What is the Earnings Per Share (EPS TTM) of Clene Inc. (CLNN)?
The Earnings Per Share (EPS TTM) of Clene Inc. (CLNN) is -2.65.